Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1508–1513. doi: 10.1128/aac.40.6.1508

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

C W Ford 1, J C Hamel 1, D M Wilson 1, J K Moerman 1, D Stapert 1, R J Yancey Jr 1, D K Hutchinson 1, M R Barbachyn 1, S J Brickner 1
PMCID: PMC163358  PMID: 8726028

Abstract

The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity against antibiotic-susceptible and -resistant gram-positive pathogens. In several mouse models of methicillin-resistant Staphylococcus aureus infection, U-100592 and U-100766 yielded oral 50% effective doses (ED50) ranging from 1.9 to 8.0 mg/kg of body weight, which compared favorably with vancomycin subcutaneous ED50 values of 1.1 to 4.4 mg/kg. Similarly, both compounds were active versus a Staphylococcus epidermidis experimental systemic infection. U-100592 and U-100766 effectively cured an Enterococcus faecalis systemic infection, with ED50 values of 1.3 and 10.0 mg/kg, and versus a vancomycin-resistant Enterococcus faecium infection in immunocompromised mice, both drugs effected cures at 12.5 and 24.0 mg/kg. Both compounds were exceptionally active in vivo against penicillin- and cephalosporin-resistant Streptococcus pneumoniae, with ED50 values ranging from 1.2 to 11.7 mg/kg in systemic infection models. In soft tissue infection models with S. aureus and E. faecalis, both compounds exhibited acceptable curative activities in the range of 11.0 to 39.0 mg/kg. U-100766 was also very active versus the Bacteroides fragilis soft tissue infection model (ED50 = 46.3 mg/kg). In combination-therapy studies, both U-100592 and U-100766 were indifferent or additive in vivo against a monomicrobic S. aureus infection in combination with other antibiotics active against gram-positive bacteria and combined as readily as vancomycin with gentamicin in the treatment of a polymicrobic S. aureus-Escherichia coli infection. U-100592 and U-100766 are potent oxazolidinones active against antibiotic-susceptible and -resistant gram-positive pathogens in experimental systemic and soft tissue infections.

Full Text

The Full Text of this article is available as a PDF (288.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988 Jan;32(1):150–152. doi: 10.1128/aac.32.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brook I., Frazier E. H. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg. 1990 Nov;125(11):1445–1451. doi: 10.1001/archsurg.1990.01410230039007. [DOI] [PubMed] [Google Scholar]
  3. Brumfitt W., Hamilton-Miller J. M. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J Antimicrob Chemother. 1988 Jun;21(6):711–720. doi: 10.1093/jac/21.6.711. [DOI] [PubMed] [Google Scholar]
  4. Daly J. S., Eliopoulos G. M., Reiszner E., Moellering R. C., Jr Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988 Jun;21(6):721–730. doi: 10.1093/jac/21.6.721. [DOI] [PubMed] [Google Scholar]
  5. Daly J. S., Eliopoulos G. M., Willey S., Moellering R. C., Jr Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988 Sep;32(9):1341–1346. doi: 10.1128/aac.32.9.1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eustice D. C., Feldman P. A., Slee A. M. The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem Biophys Res Commun. 1988 Feb 15;150(3):965–971. doi: 10.1016/0006-291x(88)90723-1. [DOI] [PubMed] [Google Scholar]
  7. Eustice D. C., Feldman P. A., Zajac I., Slee A. M. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 1988 Aug;32(8):1218–1222. doi: 10.1128/aac.32.8.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ford C. W., Hamel J. C., Stapert D., Yancey R. J. Establishment of an experimental model of a Staphylococcus aureus abscess in mice by use of dextran and gelatin microcarriers. J Med Microbiol. 1989 Apr;28(4):259–266. doi: 10.1099/00222615-28-4-259. [DOI] [PubMed] [Google Scholar]
  9. Neu H. C., Novelli A., Saha G., Chin N. X. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother. 1988 Apr;32(4):580–583. doi: 10.1128/aac.32.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Slee A. M., Wuonola M. A., McRipley R. J., Zajac I., Zawada M. J., Bartholomew P. T., Gregory W. A., Forbes M. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791–1797. doi: 10.1128/aac.31.11.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES